专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07119082B2 11β-long-chain-substituted 19-nor-17α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring 失效
标题翻译：具有21,16α-内酯环的11β-长链取代的19-去甲-17α-前 - 1,3,5（10） - 三烯-17β-
公开(公告)号：US07119082B2
公开(公告)日：2006-10-10
申请号：US10397854
申请日：2003-03-27
申请人： Gerd Mueller , Jens Hoffmann , Karl-Heinrich Fritzemeier , Alexander Hillisch
发明人： Gerd Mueller , Jens Hoffmann , Karl-Heinrich Fritzemeier , Alexander Hillisch
IPC分类号： A61K31/58 , C07J71/00
CPC分类号： C07J17/00
摘要： This invention relates to new 19-nor-17α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring with a long-chain substituent in 11β-position of general formula II in which R11 means a straight-chain alkyl radical with 6 to 17 carbon atoms, and R3 and R13 have the meanings that are explained in more detail in the description. The compounds act in a tissue-selective manner as pure antiestrogens and are suitable for the production of pharmaceutical agents because of these properties.
摘要翻译：本发明涉及具有21,16α-内酯环的新的19-nor-17α-前 - 1,3,5（10） - 三烯-17β-环，其通式II在11b位具有长链取代基其中R 11表示具有6至17个碳原子的直链烷基，R 3和R 13和R 13具有所述的含义在描述中更详细。化合物以组织选择性的方式作为纯抗雌激素起作用，并且由于这些性质而适用于制药。

2. 发明申请

US20080132476A1 SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS 审中-公开
标题翻译：取代的ESTRATRIRIES作为选择性活动的ESTROGENS
公开(公告)号：US20080132476A1
公开(公告)日：2008-06-05
申请号：US12027618
申请日：2008-02-07
申请人： Dirk KOSEMUND , Gerd Mueller , Alexander Hillisch , Karl-Heinrich Fritzemeier , Peter Muhn
发明人： Dirk KOSEMUND , Gerd Mueller , Alexander Hillisch , Karl-Heinrich Fritzemeier , Peter Muhn
IPC分类号： A61K31/56 , A61P19/08 , A61P15/08 , A61P5/24 , A61P15/02 , A61P19/02 , A61P17/06 , A61P9/00 , A61P9/12 , A61P25/28
CPC分类号： C07J41/00 , Y10S514/825 , Y10S514/843
摘要： This invention describes the new 9α-substituted estratrienes of general formula I in which R3, R7, R7′, R13, R16 as well as R17 and R17′ have the meanings that are indicated in the description and R9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds.The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.
摘要翻译：本发明描述了通式I的新的9α-取代的雌三烯，其中R 3，R 7，R 7'，R“ 13，R 16以及R 17和R 17'具有在说明书中指出的含义，是指直链或支链，任选部分或完全卤化的具有2-6个碳原子的烯基，乙炔基或丙-1-炔基，作为在体外表现出的药物活性成分对来自大鼠前列腺的雌激素受体制剂的亲和力高于来自大鼠子宫内和体内的雌激素受体制剂的亲和力，优选与子宫相比优于子宫，其生产，其治疗用途和含有新化合物的药物分配形式的优选作用。本发明还描述了这些化合物用于治疗雌激素缺乏诱导的疾病和病症的用途。

3. 发明授权

US07414043B2 9-α-substituted estratrienes as selectively active estrogens 失效
标题翻译： 9-α-取代的雌三醇作为选择性活性雌激素
公开(公告)号：US07414043B2
公开(公告)日：2008-08-19
申请号：US10458735
申请日：2003-06-11
申请人： Dirk Kosemund , Gerd Mueller , Alexander Hillisch , Karl-Heinrich Fritzemeier , Peter Muhn
发明人： Dirk Kosemund , Gerd Mueller , Alexander Hillisch , Karl-Heinrich Fritzemeier , Peter Muhn
IPC分类号： A61K31/56 , C07J1/00
CPC分类号： C07J41/00 , Y10S514/825 , Y10S514/843
摘要： This invention describes the new 9α-substituted estratrienes of general formula I in which R3, R7, R7′, R13, R16 as well as R17 and R17′ have the meanings that are indicated in the description and R9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.
摘要翻译：本发明描述了通式I的新的9α-取代的雌三烯，其中R 3，R 7，R 7'，R“ 13，R 16以及R 17和R 17'具有在说明书中指出的含义，是指具有2-6个碳原子的直链或支链，任选部分或完全卤化的烯基，乙炔基或丙-1-茚基，作为在体外表现出的药物活性成分对来自大鼠前列腺的雌激素受体制剂的亲和力高于来自大鼠子宫内和体内的雌激素受体制剂的亲和力，优选与子宫相比优于子宫，其生产，其治疗用途和含有新化合物的药物分配形式的优选作用。本发明还描述了这些化合物用于治疗雌激素缺乏诱导的疾病和病症的用途。

4. 发明授权

US07109360B1 16-hydroxyestratrienes as selectively active estrogens 失效
标题翻译： 16-羟基三烯作为选择性活性雌激素
公开(公告)号：US07109360B1
公开(公告)日：2006-09-19
申请号：US09497891
申请日：2000-02-04
申请人： Hermann Kuenzer , Rudolf Knauthe , Monika Lessl , Karl-Heinrich Fritzemeier , Christa Hegele-Hartung , Ulf Boemer , Gerd Mueller , Dirk Kosemund
发明人： Hermann Kuenzer , Rudolf Knauthe , Monika Lessl , Karl-Heinrich Fritzemeier , Christa Hegele-Hartung , Ulf Boemer , Gerd Mueller , Dirk Kosemund
IPC分类号： C07J9/00 , C07J41/00
CPC分类号： A61K31/565 , C07J1/00 , C07J9/00 , C07J41/00
摘要： The invention describes new compounds as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action on bone rather than the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds.The new compounds are 16α- and 16β-hydroxy-estra-1,3,5(10)-estratrienes, which carry additional substituents on the steroid skeleton and can have one or more additional double bonds in the B-, C- and/or D-rings.
摘要翻译：本发明描述了作为药物活性成分的新化合物，其具有体外对来自大鼠前列腺的雌激素受体制剂的亲和力高于来自大鼠子宫的雌激素受体制剂，并且在体内对骨骼而不是子宫的优先作用，其产生，其治疗使用和含有新化合物的药物分配形式。新化合物是16α-和16beta-羟基 - 雌-1,3,5（10） - 三亚甲基，其在类固醇骨架上携带另外的取代基，并且可以在B-，C-和/ 或D形环。

5. 发明申请

US20060270845A1 16-Hydroxyestratrienes as selectively active estrogens 审中-公开
标题翻译： 16羟基三烯作为选择性活性雌激素
公开(公告)号：US20060270845A1
公开(公告)日：2006-11-30
申请号：US11498109
申请日：2006-08-03
申请人： Hermann Kuenzer , Rudolf Knauthe , Monika Lessl , Karl-Heinrich Fritzemeier , Christa Hegele-Hartung , Ulf Boemer , Gerd Mueller , Dirk Kosemund
发明人： Hermann Kuenzer , Rudolf Knauthe , Monika Lessl , Karl-Heinrich Fritzemeier , Christa Hegele-Hartung , Ulf Boemer , Gerd Mueller , Dirk Kosemund
IPC分类号： C07J41/00 , C07J1/00
CPC分类号： A61K31/565 , C07J1/00 , C07J9/00 , C07J41/00
摘要： The invention describes new compounds as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action on bone rather than the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The new compounds are 16α- and 16β-hydroxy-estra-1,3,5(10)-estratrienes, which carry additional substituents on the steroid skeleton and can have one or more additional double bonds in the B-, C- and/or D-rings.
摘要翻译：本发明描述了作为药物活性成分的新化合物，其具有体外对来自大鼠前列腺的雌激素受体制剂的亲和力高于来自大鼠子宫的雌激素受体制剂，并且在体内对骨骼而不是子宫的优先作用，其产生，其治疗使用和含有新化合物的药物分配形式。新化合物是16α-和16beta-羟基 - 雌-1,3,5（10） - 三亚甲基，其在类固醇骨架上携带另外的取代基，并且可以在B-，C-和/ 或D形环。

6. 发明申请

US20050020695A1 Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor 审中-公开
标题翻译：使用ERbeta选择性配体调节生育力和有用的化合物
公开(公告)号：US20050020695A1
公开(公告)日：2005-01-27
申请号：US10909540
申请日：2004-08-03
申请人： Christa Hegele-Hartung , Karl-Heinrich Fritzemeier , Hiroshi Yamanouchi , Olaf Peters , Dirk Kosemund , Gerd Mueller , Ingo Tornus , Gerd Schubert , Sven Ring
发明人： Christa Hegele-Hartung , Karl-Heinrich Fritzemeier , Hiroshi Yamanouchi , Olaf Peters , Dirk Kosemund , Gerd Mueller , Ingo Tornus , Gerd Schubert , Sven Ring
IPC分类号： A61K31/00 , A61K31/05 , A61K31/122 , A61K45/06 , A61K31/075 , C07C39/12
CPC分类号： A61K45/06 , A61K31/00 , A61K31/05 , A61K31/122
摘要： The present invention discloses the use of ERβ-selective ligands for production of medicaments for regulating fertility without additional use of a progestin. ERβ-agonists are used for treatment of infertility and ERβ-antagonists for contraception.
摘要翻译：本发明公开了ERbeta选择性配体用于生产用于调节生育力而不需要额外使用孕激素的药物。 ERbeta激动剂用于治疗不育症和ERbeta拮抗剂用于避孕。

7. 发明授权

US06794409B2 Use of ER&bgr;-selective ligands for regulating fertility and compounds useful therefor 失效
标题翻译：使用ERbeta选择性配体调节生育力和有用的化合物
公开(公告)号：US06794409B2
公开(公告)日：2004-09-21
申请号：US10083685
申请日：2002-02-27
申请人： Christa Hegele-Hartung , Karl-Heinrich Fritzemeier , Hiroshi Yamanouchi , Olaf Peters , Dirk Kosemund , Gerd Mueller , Ingo Tornus , Gerd Schubert , Sven Ring
发明人： Christa Hegele-Hartung , Karl-Heinrich Fritzemeier , Hiroshi Yamanouchi , Olaf Peters , Dirk Kosemund , Gerd Mueller , Ingo Tornus , Gerd Schubert , Sven Ring
IPC分类号： A61K31215
CPC分类号： A61K45/06 , A61K31/00 , A61K31/05 , A61K31/122
摘要： The present invention discloses the use of ER&bgr;-selective ligands for production of medicaments for regulating fertility without additional use of a progestin. ER&bgr;-agonists are used for treatment of infertility and ER&bgr;-antagonists for contraception.
摘要翻译：本发明公开了ERbeta选择性配体用于生产用于调节生育力的药物的用途，而不需要额外使用孕激素.Ebeta激动剂用于治疗不育症和用于避孕的ERbeta拮抗剂。

8. 发明授权

US07938983B2 Illumination system comprising a radiation source and a fluorescent material 有权
标题翻译：包括辐射源和荧光材料的照明系统
公开(公告)号：US07938983B2
公开(公告)日：2011-05-10
申请号：US11371883
申请日：2006-03-08
申请人： Regina Mueller-Mach , Gerd Mueller , Jörg Meyer , Peter J. Schmidt , Walter Mayr , Hans-Dieter Bausen
发明人： Regina Mueller-Mach , Gerd Mueller , Jörg Meyer , Peter J. Schmidt , Walter Mayr , Hans-Dieter Bausen
IPC分类号： H01L33/00 , C09K11/59
CPC分类号： C09K11/7792 , C04B35/581 , C04B35/584 , C04B2235/3201 , C04B2235/3206 , C04B2235/3208 , C04B2235/3224 , C04B2235/3852 , C04B2235/3865 , C04B2235/3873 , C04B2235/444 , C04B2235/445 , C09K11/0883 , C09K11/565 , C09K11/7721 , C09K11/7731 , C09K11/7734 , C09K11/7739 , C09K11/7768 , C09K11/7774 , H01L2224/48091 , H01L2224/73265 , H01L2224/8592 , H01L2924/181 , H05B33/14 , Y02B20/181 , H01L2924/00014 , H01L2924/00012
摘要： The invention concerns an illumination system for generation of colored, especially amber or red light, comprising a radiation source and a fluorescent material comprising at least one phosphor capable of absorbing a part of light emitted by the radiation source and emitting light of wavelength different from that of the absorbed light; wherein said at least one phosphor is a amber to red emitting a rare earth metal-activated oxonitridoalumosilicate of general formula (Ca1−x−y−zSrxBayMgz)1−n(Al1−a+bBa)Si1−bN3−bOb:REn, wherein 0≦x≦1, 0≦y≦1, 0≦z≦1, 0≦a≦1, 0
摘要翻译：本发明涉及一种用于产生着色的，特别是琥珀色或红色光的照明系统，其包括辐射源和荧光材料，该荧光材料包括至少一种能够吸收由该辐射源发射的光的一部分的荧光体，并发射与该辐射源不同的波长的吸收光; 其中所述至少一种荧光体是琥珀色以红色发射通式为（Ca1-x-y-zSrxBayMgz）1-n（Al1-a + bBa）Si1-bN3-bOb：REn的稀土金属 - 活化的氧杂氮杂钨酸硅酸盐，其中 0＆nlE; x＆nlE; 1,0和nlE; y＆nlE; 1,0和nlE; z＆nlE; 1,0和nlE; a＆nlE; 1,0

9. 发明申请

US20080023712A1 Phosphor Converted Light Emitting Device 有权
标题翻译：荧光粉转换发光装置
公开(公告)号：US20080023712A1
公开(公告)日：2008-01-31
申请号：US11623068
申请日：2007-01-13
申请人： Gerd Mueller , Regina Mueller-Mach , Thomas Juestel , Petra Huppertz , Detlef Wiechert , Dominik Uhlich
发明人： Gerd Mueller , Regina Mueller-Mach , Thomas Juestel , Petra Huppertz , Detlef Wiechert , Dominik Uhlich
IPC分类号： H01L33/00
CPC分类号： C09K11/7788 , C04B35/01 , C04B35/16 , C04B2235/3208 , C04B2235/3213 , C04B2235/3222 , C04B2235/3224 , C04B2235/3225 , C04B2235/3286 , C04B2235/3287 , C04B2235/764 , C04B2235/9661 , C09K11/7735 , C09K11/7792
摘要： A phosphor converted light emitting device includes a semiconductor structure comprising a light emitting layer disposed between an n-type region and a p-type region, the light emitting layer being configured to emit light having a first peak wavelength; a first phosphor configured to emit light having a second peak wavelength; and a second phosphor configured to emit light having a third peak wavelength. The second phosphor is an Eu3+-activated phosphor, configured such that in the excitation spectrum at 298K and 1.013 bar, a maximum intensity in a wavelength range between 460 nm and 470 nm is at least 5% of a maximum intensity in a wavelength range between 220 nm to 320 nm.
摘要翻译：荧光体转换发光器件包括：半导体结构，包括设置在n型区域和p型区域之间的发光层，所述发光层被配置为发射具有第一峰值波长的光; 配置为发射具有第二峰值波长的光的第一荧光体; 以及配置为发射具有第三峰值波长的光的第二荧光体。第二荧光体是Eu 3+激活的磷光体，其被配置为使得在298K和1.013巴的激发光谱中，在460nm和470nm之间的波长范围内的最大强度为至少5％在220nm至320nm之间的波长范围内具有最大强度。

10. 发明授权

US06351069B1 Red-deficiency-compensating phosphor LED 有权
标题翻译：红色补偿荧光粉LED
公开(公告)号：US06351069B1
公开(公告)日：2002-02-26
申请号：US09252207
申请日：1999-02-18
申请人： Christopher H. Lowery , Gerd Mueller , Regina Mueller
发明人： Christopher H. Lowery , Gerd Mueller , Regina Mueller
IPC分类号： H05B3314
CPC分类号： H01L33/504
摘要： A light emitting device and a method of fabricating the device utilize a supplementary fluorescent material that radiates secondary light in the red spectral region of the visible light spectrum to increase the red color component of the composite output light. The secondary light from the supplementary fluorescent material allows the device to produce “white” output light that is well-balanced with respect to color for true color rendering applications. The supplementary fluorescent material is included in a fluorescent layer that is positioned between a die and a lens of the device. The die is preferably a GaN based die that emits light having a peak wavelength of 470 nm. The fluorescent layer also includes a main fluorescent material. Preferably, the main fluorescent material is Cerium (Ce) activated and Gadolinium (Gd) doped Yttrium Aluminum Garnet (YAG) phosphor (“Ce:YAG phosphor”). In a first preferred embodiment, the supplementary fluorescent material is a compound that is produced by doping the Ce:YAG phosphor with a trivalent ion of Praseodymium (Pr). In a second preferred embodiment, the supplementary fluorescent material is Europium (Eu) activated Strontium Sulphide (SrS) phosphor. The amount of supplementary phosphor in the fluorescent layer can vary depending on the amount of red color that may be required in the white output light. The exact amount of supplementary phosphor is not critical to the invention.
摘要翻译：发光器件和制造该器件的方法利用在可见光谱的红色光谱区域中辐射次级光的辅助荧光材料以增加复合输出光的红色分量。来自辅助荧光材料的二次光允许该装置产生相对于真彩色渲染应用的颜色平衡良好的“白色”输出光。辅助荧光材料包括在位于模具和装置的透镜之间的荧光层中。芯片优选是发射峰值波长为470nm的光的GaN基管芯。荧光层还包括主荧光材料。优选地，主荧光材料是铈（Ce）活化的和掺杂钆（Gd）的钇铝石榴石（YAG）荧光体（“Ce：YAG磷”）。在第一优选实施方案中，辅助荧光材料是通过用三价镨（Pr）离子掺杂Ce:YAG荧光体而制备的化合物。在第二优选实施方案中，辅助荧光材料是铕（Eu）活化的硫化锶（SrS）荧光体。荧光层中的补充磷光体的量可以根据白色输出光中可能需要的红色的量而变化。补充磷光体的确切量对本发明不是关键的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式